Moreover, IKAROS proteins are destructed by lenalidomide [72,73], a drug shown to act on CLL cells in vitro [74] and tested in the CLLM1 trial, where it improved progression-free survival. This evidence concerns the gene IKZF1 and B-cell chronic lymphocytic leukemia.